Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Early Phase 1

Active, not recruiting

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: Trametinib
Drug: Paclitaxel

First Posted Date: 2017-03-21

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 13

Registration Number: NCT03085056

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Phase 1

Active, not recruiting

Conditions: Refractory
Relapsed
Chronic Lymphocytic Leukemia (CLL)

Interventions: Biological: EGFRt/19-28z/4-1BBL CAR T cells

First Posted Date: 2017-03-21

Last Posted Date: 2024-06-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT03085173

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Dye for the Detection of Cancer of the Tongue and Mouth

Phase 1

Recruiting

Conditions: Oral Squamous Cell Carcinoma (OSCC)

Interventions: Drug: Olaparib

First Posted Date: 2017-03-21

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT03085147

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

and more 4 locations

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Myeloid Hematologic Malignancy
Lymphoid Hematologic Malignancy

Interventions: Drug: Ixazomib

First Posted Date: 2017-03-17

Last Posted Date: 2022-09-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT03082677

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

Active, not recruiting

Conditions: High-Risk Nevus Phenotype

Interventions: Behavioral: survey
Other: Saliva samples

First Posted Date: 2017-03-15

Last Posted Date: 2024-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 73

Registration Number: NCT03080948

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 1 locations

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

Phase 2

Active, not recruiting

Conditions: Intestinal Microbiome
Febrile Neutropenia

Interventions: Drug: cefepime
Drug: Piperacillin-tazobactam

First Posted Date: 2017-03-13

Last Posted Date: 2024-11-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 347

Registration Number: NCT03078010

Locations: 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Phase 1

Completed

Conditions: Lung Cancer
Recurrent Lung Adenocarcinoma
Lung Adenocarcinoma
Lung Cancer Metastatic
Lung Cancer Stage IV
Recurrent Lung Cancer

Interventions: Drug: Trametinib
Drug: Erlotinib

First Posted Date: 2017-03-10

Last Posted Date: 2024-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT03076164

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma
Epithelioid Sarcoma
Cutaneous Angiosarcoma

Interventions: Drug: Talimogene Laherparepvec (T-VEC)
Drug: Pembrolizumab

First Posted Date: 2017-03-03

Last Posted Date: 2024-07-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 41

Registration Number: NCT03069378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
MD Anderson Cancer Center (Data Analysis Only), Houston, Texas, United States
🇺🇸
Enable Medicine (Specimen Analysis Only), Menlo Park, California, United States

and more 2 locations

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Myelofibrosis

Interventions: Drug: Ruxolitinib
Drug: Thalidomide

First Posted Date: 2017-03-03

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03069326

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 4 locations

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Diagnostic Test: Breast Magnetic Resonance Imaging (MRI)
Diagnostic Test: Contrast Enhanced Mammography (CEDM)

First Posted Date: 2017-03-03

Last Posted Date: 2023-11-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 125

Registration Number: NCT03070340

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States

and more 2 locations

Home Terms & Conditions Privacy Policy